An ApoB100-mimetic vaccine prevents obesity and liver steatosis in ApoE-/- mice

Su Kang Kong, Moon Kyung Choe, Hyung Ji Kim, Young Sik Kim, Bert Binas, Hyo Joon Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Recently, a peptide vaccine (B4T) was developed that prevents high fat diet (HFD)-induced obesity and liver steatosis in wild type mice and appears to target an epitope present in ApoB100 but not ApoB48. Here, we ask whether B4T remains effective in ApoE knockout (ApoE-ko) mice, which exhibit a greatly increased ApoB48/ApoB100 ratio and develop atherosclerosis under HFD. Methods HFD-fed male ApoE-ko mice were injected with B4T or vehicle 3 times between 5 and 15 weeks of age. Until 45 weeks of age, they were regularly weighed and antibody titers determined. In the end, adiposity and organ histologies were examined. Results We find that in the ApoE-ko mice, B4T prevents HFD-induced body weight increases (p < 0.01) to a comparable degree as previously shown in wild type mice. Also, liver steatosis was prevented as previously shown in wild type mice. By contrast, atherosclerotic plaque formation was not prevented in any of the vaccinated mice studied, in line with the observation that antibody production paralleled the weight reduction but largely preceded atherogenesis. Conclusion The findings demonstrate effectiveness of B4T despite the increased ApoB48/B100 ratio, but argue against an effect on de novo plaque formation. At least under the current vaccination schedule, the obesity- and atherosclerosis-related roles of ApoB appear to be dissociable.

Original languageEnglish
Pages (from-to)1140-1144
Number of pages5
JournalPharmacological Reports
Volume69
Issue number6
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Apolipoprotein B-48
High Fat Diet
Apolipoproteins E
Fatty Liver
Vaccines
Obesity
Knockout Mice
Atherosclerosis
Subunit Vaccines
Adiposity
Apolipoproteins B
Atherosclerotic Plaques
Antibody Formation
Weight Loss
Epitopes
Histology
Appointments and Schedules
Vaccination
Body Weight
Antibodies

Keywords

  • Apolipoprotein B
  • Apolipoprotein E
  • Atherosclerosis
  • Obesity
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology

Cite this

An ApoB100-mimetic vaccine prevents obesity and liver steatosis in ApoE-/- mice. / Kong, Su Kang; Choe, Moon Kyung; Kim, Hyung Ji; Kim, Young Sik; Binas, Bert; Kim, Hyo Joon.

In: Pharmacological Reports, Vol. 69, No. 6, 01.12.2017, p. 1140-1144.

Research output: Contribution to journalArticle

Kong, Su Kang ; Choe, Moon Kyung ; Kim, Hyung Ji ; Kim, Young Sik ; Binas, Bert ; Kim, Hyo Joon. / An ApoB100-mimetic vaccine prevents obesity and liver steatosis in ApoE-/- mice. In: Pharmacological Reports. 2017 ; Vol. 69, No. 6. pp. 1140-1144.
@article{8264a2ec1edf464687ca3716a8e7e376,
title = "An ApoB100-mimetic vaccine prevents obesity and liver steatosis in ApoE-/- mice",
abstract = "Background Recently, a peptide vaccine (B4T) was developed that prevents high fat diet (HFD)-induced obesity and liver steatosis in wild type mice and appears to target an epitope present in ApoB100 but not ApoB48. Here, we ask whether B4T remains effective in ApoE knockout (ApoE-ko) mice, which exhibit a greatly increased ApoB48/ApoB100 ratio and develop atherosclerosis under HFD. Methods HFD-fed male ApoE-ko mice were injected with B4T or vehicle 3 times between 5 and 15 weeks of age. Until 45 weeks of age, they were regularly weighed and antibody titers determined. In the end, adiposity and organ histologies were examined. Results We find that in the ApoE-ko mice, B4T prevents HFD-induced body weight increases (p < 0.01) to a comparable degree as previously shown in wild type mice. Also, liver steatosis was prevented as previously shown in wild type mice. By contrast, atherosclerotic plaque formation was not prevented in any of the vaccinated mice studied, in line with the observation that antibody production paralleled the weight reduction but largely preceded atherogenesis. Conclusion The findings demonstrate effectiveness of B4T despite the increased ApoB48/B100 ratio, but argue against an effect on de novo plaque formation. At least under the current vaccination schedule, the obesity- and atherosclerosis-related roles of ApoB appear to be dissociable.",
keywords = "Apolipoprotein B, Apolipoprotein E, Atherosclerosis, Obesity, Vaccine",
author = "Kong, {Su Kang} and Choe, {Moon Kyung} and Kim, {Hyung Ji} and Kim, {Young Sik} and Bert Binas and Kim, {Hyo Joon}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.pharep.2017.05.019",
language = "English",
volume = "69",
pages = "1140--1144",
journal = "Pharmacological Reports",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "6",

}

TY - JOUR

T1 - An ApoB100-mimetic vaccine prevents obesity and liver steatosis in ApoE-/- mice

AU - Kong, Su Kang

AU - Choe, Moon Kyung

AU - Kim, Hyung Ji

AU - Kim, Young Sik

AU - Binas, Bert

AU - Kim, Hyo Joon

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background Recently, a peptide vaccine (B4T) was developed that prevents high fat diet (HFD)-induced obesity and liver steatosis in wild type mice and appears to target an epitope present in ApoB100 but not ApoB48. Here, we ask whether B4T remains effective in ApoE knockout (ApoE-ko) mice, which exhibit a greatly increased ApoB48/ApoB100 ratio and develop atherosclerosis under HFD. Methods HFD-fed male ApoE-ko mice were injected with B4T or vehicle 3 times between 5 and 15 weeks of age. Until 45 weeks of age, they were regularly weighed and antibody titers determined. In the end, adiposity and organ histologies were examined. Results We find that in the ApoE-ko mice, B4T prevents HFD-induced body weight increases (p < 0.01) to a comparable degree as previously shown in wild type mice. Also, liver steatosis was prevented as previously shown in wild type mice. By contrast, atherosclerotic plaque formation was not prevented in any of the vaccinated mice studied, in line with the observation that antibody production paralleled the weight reduction but largely preceded atherogenesis. Conclusion The findings demonstrate effectiveness of B4T despite the increased ApoB48/B100 ratio, but argue against an effect on de novo plaque formation. At least under the current vaccination schedule, the obesity- and atherosclerosis-related roles of ApoB appear to be dissociable.

AB - Background Recently, a peptide vaccine (B4T) was developed that prevents high fat diet (HFD)-induced obesity and liver steatosis in wild type mice and appears to target an epitope present in ApoB100 but not ApoB48. Here, we ask whether B4T remains effective in ApoE knockout (ApoE-ko) mice, which exhibit a greatly increased ApoB48/ApoB100 ratio and develop atherosclerosis under HFD. Methods HFD-fed male ApoE-ko mice were injected with B4T or vehicle 3 times between 5 and 15 weeks of age. Until 45 weeks of age, they were regularly weighed and antibody titers determined. In the end, adiposity and organ histologies were examined. Results We find that in the ApoE-ko mice, B4T prevents HFD-induced body weight increases (p < 0.01) to a comparable degree as previously shown in wild type mice. Also, liver steatosis was prevented as previously shown in wild type mice. By contrast, atherosclerotic plaque formation was not prevented in any of the vaccinated mice studied, in line with the observation that antibody production paralleled the weight reduction but largely preceded atherogenesis. Conclusion The findings demonstrate effectiveness of B4T despite the increased ApoB48/B100 ratio, but argue against an effect on de novo plaque formation. At least under the current vaccination schedule, the obesity- and atherosclerosis-related roles of ApoB appear to be dissociable.

KW - Apolipoprotein B

KW - Apolipoprotein E

KW - Atherosclerosis

KW - Obesity

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85033451544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033451544&partnerID=8YFLogxK

U2 - 10.1016/j.pharep.2017.05.019

DO - 10.1016/j.pharep.2017.05.019

M3 - Article

VL - 69

SP - 1140

EP - 1144

JO - Pharmacological Reports

JF - Pharmacological Reports

SN - 1734-1140

IS - 6

ER -